Nederlands tijdschrift voor geneeskunde最新文献

Objective: Risk minimisation measures (RMM) are put in place to ensure safe and effective use of medicines. This study assessed whether RMM for five medicines are implemented in Dutch clinical guidelines.

Design: Descriptive study.

Method: Dutch clinical guidelines where treatment with valproate, fluoroquinolones, methotrexate, metformin or fluorouracil was recommended were identified. In those guidelines that had been updated after publication of the RMM, we determined whether RMM-information was included in the guideline.

Results: Out of 50 identified guidelines recommending treatment with one of the five medicines, only 21 (42%) were revised after RMM-implementation. Of these 21 guidelines, 12 (n = 57%) included RMM-related information.

Conclusion: Uptake of RMM information in Dutch clinical guidelines is limited and RMM-publication does not prompt guideline updates. This suggests that guidelines alone are not an optimal way to inform health care professionals of new safety warnings.

The Dutch Act on Patients Rights requires that physicians record all forms of treatment in the medical file of the patient concerned. This obligation ends once the patient dies. Do family members of the deceased patient then have the right to consult the medical file? This question regularly emerges when family members question the competence of a deceased person, notably when the latter before its death changed its will. According to the Act on Patients Rights access to the medical file of a deceased person by relatives is restricted to three situations. In these cases the treating physicians is required to provide access. Family members do not have the right to require the treating physician to retrospectively report on the competence of the deceased person. Family members can only ask an independent physician to advice on the competence of the deceased individual.

When making critical treatment decisions, shared decision-making (SDM) between healthcare providers and patients is essential. SDM involves discussing care options, considering patient preferences, and ensuring decisions align with patient values and medical conditions. This process becomes challenging in life-threatening emergencies, where time constraints hinder thorough discussions and coordination among healthcare providers, potentially leading to inappropriate care. Two cases highlight these challenges. Patient A, a 76-year-old man with acute aortic dissection, underwent surgery without comprehensive SDM, resulting in unsuccessful outcomes and questioning the appropriateness of the intervention. Patient B, an 84-year-old man with heart failure and COPD, received palliative care following thorough SDM and multidisciplinary consultation, leading to a dignified end-of-life experience. We conclude that effective communication and multidisciplinary collaboration are crucial for SDM, even in acute settings. Recommendations include creating space for thorough discussions, involving all relevant healthcare providers, and integrating palliative care as a serious treatment option. This approach ensures patient-centered care and aligns medical interventions with the patient's values and needs.

Drug-induced QT prolongation increases the risk of Torsade de Pointes (TdP). Drug-induced QT prolongation is a complex and unpredictable system due to many uncertainties. Risk factors such as electrolyte disturbances, heart failure and genetics play an important role in estimating the effect on QT prolongation. Moreover, the degree of QT prolongation is not always directly related to the risk of TdP and the assessment of the QT-interval is variable depending on the type and timing of QT measurement. Therefore, the variation in QT measurement may be larger than the effect of certain drugs on the QT interval. Because of the potentially lethal risk, several measures are undertaken to reduce the risk of QT prolongation and TdP, while their effect and proportionality are unclear. We suggest we should be less stringent in certain settings when risk of TdP is extremely low given the limited availability of our resources.

Almost all laboratories in The Netherlands report an estimated glomerular filtration rate (eGFR) whenever a value for plasma creatinine is requested. This formula is based on gender and age, besides the plasma creatinine concentration, and sometimes also a correction for race is applied. While this GFR reporting improved the recognition of chronic kidney disease, the formulas used have intrinsic limitations. Moreover, recently a novel formula that obviates the need for a correction factor for race has been proposed. In this article the strengths and weaknesses of plasma creatinine and formulas based on that are discussed, following ten frequently asked questions.

Glomerular filtration rate (GFR) serves as a marker for various renal functions. Different formulas are available to calculate an estimated GFR (eGFR), which are commonly based on serum creatinine, age, and sex. However, the eGFR merely reflects GFR under specific conditions. Due to the multitude of functions of the kidney, it is not possible to capture all aspects in one value. To diagnose renal diseases comprehensively, not only eGFR but also urine analysis and clinical context should be considered. Interpretation of eGFR for renal function monitoring requires careful consideration of factors such as (blood pressure) medication, diabetes, obesity, and pregnancy. Combining various laboratory parameters with a patient's clinical context provides an overview of the different functions of the kidney and its consequences for the patient.

Background: Advanced heart failure is defined as severe cardiac dysfunction combined with hospital admissions due to heart failure and major functional limitations. Selected patients with advanced heart failure can be treated with a left ventricular assist device. Patients with the newest generation of devices have a five-year survival of approximately 60%.

Case description: We describe the case of a 54-year-old patient with advanced heart failure due to coronary artery disease, who was referred from a secondary to a tertiary care center to evaluate candidacy for LVAD therapy. Due to significant multimorbidity and unhealthy lifestyle (BMI 33 kg/m2, eGFR 29 ml/min/1.73m2, smoking, peripheral vascular disease, very poorly controlled diabetes mellitus), the patient was not considered a suitable candidate. Due to a rigorous change in his lifestyle, a number of (relative) contraindications changed in such a way that an LVAD was successfully implanted in the patient with a good functional status afterwards.

Conclusion: Candidacy for LVAD therapy is determined on an individual basis through a vigilant screening process. Eligibility for this treatment can be positively influenced by a change in lifestyle. Intensive guidance of care providers is important in this respect.

The differential diagnosis of a rapidly enlarging neck mass consists of many different benign ((haemorrhagic) cyst) and malignant (anaplastic thyroid cancer (ATC) and lymphoma) causes. ATC is a rare disease with a median survival of 6 months. As early diagnosis and management are key for fast-growing cancers, in our centre we have implemented a dedicated short-stay in-hospital fast-track diagnostic work-up for patients with a rapid growing mass in the neck. The goal of this track is to have a fast diagnostic and therapeutic plan for this disease. Based on three clinical cases we discuss our experience with this fast-track diagnostic work-up for rapidly growing mass in the neck and illustrate the additional value in this clinical entity.

A 38-year-old woman with urosepsis and persistent unilateral hydronephrosis after antibiotic treatment. Antegrade pyelogram shows urine flow obstruction to the bladder. The whole ureter shows multiple small smooth-walled round lucent filling defects projecting into the lumen. The diagnosis ureteritis cystica was made.

Eating disorders, such as anorexia, bulimia and binge eating disorder, are a common mental health problem, but are even so easily missed in the medical field. Patients experience a lot of shame to come up with their eating problem. Doctors tend to forget asking for eating pattern and purging when a patient has a normal weight or is obese. A third of the obese population experience binges. A relatively new diagnose is ARFID (avoidant restrictive food intake disorder). Patients are not scared to gain weight, but have nutritional deficits because of not being able to eat, forgetting to eat or eating only a couple of products. Motivating patients to seek treatment is challenging. Understanding their struggles, knowing the complications and what to examine is important. The article gives an overview how to diagnose and examine eating disorders and when and where to refer to.